-
BeiGene Announces Supply Update for ABRAXANE® in China
BeiGene
March 26, 2020
NMPA has suspended the importation, sales and use of ABRAXANE in China supplied by Celgene Corporation, a Bristol Myers Squibb (BMS) company; As the marketing agent for ABRAXANE in China, BeiGene is working with BMS to restore supply in China.
-
BMS secures FDA priority review for NSCLC treatment combination
pharmaceutical-technology
January 17, 2020
Bristol-Myers Squibb Company (BMS) has secured the US Food and Drug Administration (FDA) priority review for a drug combination to treat metastatic or recurrent non-small cell lung cancer (NSCLC).
-
BMS’ Orencia gets breakthrough status in US to prevent GvHD
pharmaceutical-technology
December 09, 2019
Bristol-Myers Squibb (BMS) has received breakthrough device designation for its Orencia (abatacept) drug to prevent moderate to severe acute graft-versus-host disease (GvHD).
-
PTC Therapeutics Expands in New Jersey
contractpharma
August 06, 2019
Secures BMS biologics facility to support gene therapy production.
-
Nektar Therapeutics, BMS Receive Breakthrough Therapy Designation
contractpharma
August 02, 2019
Bempegaldesleukin in combination with Bristol-Myers Squibb's Opdivo aims to treat patients with untreated advanced melanoma.
-
Can BMS parlay its surprise 'win and a miss' in first-line lung cancer into a net gain?
fiercepharma
July 28, 2019
If you thought you knew what was coming in Bristol-Myers Squibb’s CheckMate-227 trial, forget it.
-
BMS’ Opdivo fails to meet primary endpoint in NSCLC
pharmaceutical-technology
July 26, 2019
Bristol-Myers Squibb (BMS) has announced that its immunotherapy Opvido (nivolumab) plus chemotherapy failed to meet its primary endpoint of overall survival (OS) in the Phase III CheckMate-227 trial of patients with first-line non-squamous non-small cell
-
Bayer, BMS, Ono to Collaborate on Colorectal Cancer Treatments
contractpharma
July 19, 2019
Aims to evaluate the combination of Bayer's Stivarga and BMS / Ono's Opdivo in patients with MSS mCRC.
-
Draper, BMS Sign Toxicity Testing Pact
contractpharma
July 01, 2019
Companies to develop unique liver tissue model for screening toxicity of drugs.
-
BMS to divest Otezla for approval of $74bn merger with Celgene
pharmaceutical-technology
June 26, 2019
Bristol-Myers Squibb (BMS) has offered to divest prescription medicine Otezla in order to receive approval for its $74bn merger with Celgene from the US Federal Trade Commission (FTC).